Pfizer's Potential $7.3 Billion Move in Anti-Obesity Market
Pfizer is reportedly nearing a $7.3 billion acquisition of Metsera, a developer of anti-obesity medications. Reports suggest Pfizer will pay $47.50 per share, with an additional $22.50 contingent on milestone achievements. An official announcement could come soon, although confirmation from Reuters is currently pending.
Pfizer is reportedly on the brink of acquiring Metsera, an anti-obesity drug developer, in a deal worth up to $7.3 billion, according to the Financial Times. Current plans detail an initial payment of $47.50 per share, with the potential for additional funds based on performance milestones.
The anticipated announcement might be officially made as soon as Monday. However, Reuters has not been able to independently verify the report as of now.
Neither Metsera nor Pfizer has commented on the matter when approached by Reuters outside of normal business operating hours.
- READ MORE ON:
- Pfizer
- Metsera
- takeover
- anti-obesity
- drug
- acquisition
- Financial Times
- Reuters
- market
- health
Advertisement
ALSO READ
Pfizer Eyes $7.3 Billion Acquisition of Metsera in Weight-Loss Drug Market Sweep
Pfizer's Strategic Move: Potential $7.3 Billion Acquisition of Metsera Set to Shake Up Weight-Loss Drug Market
Pfizer Eyes $7.3 Billion Acquisition of Metsera
Innovations in Health: US Drug Plans, Neuralink Trials, and FDA Approvals
Odisha CM Rallies Youth for a Drug-Free India
Google News